• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

• 페이스북 공유
• 트위터 공유
• 

Objective: Assess the security and efficacy of upcoming stem cell treatments and analyze their results on the cognitive and behavioral impairments in patients diagnosed with autism.

Methods: We included managed and noncontrolled, randomized and non-randomized trials evaluating stem cell therapy as a remedy in patients with autism spectrum disorder compared to placebo or without comparator.

Data sources: Scopus, Web of Science, MEDLINE and EMBASE. Risk of bias was assessed utilizing Cochrane's Risk of Bias tool and the NIH's Quality Assessment Tool for Studies With No Control Group.

Results: Eleven trials together with 461 patients proved eligible. ABC scale meta-evaluation showed a mean uncooked of -11.Ninety seven within the intervention teams (ninety five % CI -91.Forty five to 67.52, p < 0.01). CARS scale reported a mean raw of -9.08 (95 % CI -15.43 to -2.73, p < 0.01). VABS scale was reported by their domains: communication domain reported a mean raw of 2.69 (95 % CI 1.30 to 4.08, p = 0.92); daily living domain, 1.99 (95 % CI 0.83 to 3.15, p = 0.51); motor domain, 1.06 (95 % CI -0.37 to 2.48, p = 0.20); socialization domain, 3.09 (95 % CI 1.71 to 4.48, p = 0.61); adaptive behavior domain, 2.10 (95 % CI 1.04 to 3.16, p = 0.36). Furthermore, the most common side effects reported included fever, hyperactivity, vomit, headache, and aggressiveness; no serious adverse events were reported.

Conclusions: The physique of evidence suggests that stem cell therapy considerably improves scales in patients with autism spectrum disorder, hence, future research ought to assist us have more confidence in the outcomes. We discovered no critical adversarial occasions related to the stem cell therapy.

If you have any type of questions concerning where and how you can use https://autismtreatmentcare.com/, you can contact us at our web site.